Fibroblast Growth Factor 21 as a Marker of Prediabetes in Patients with Non-alcoholic Fatty Liver Disease

Background: Fibroblast growth factor 21 is a peptide primarily secreted by the liver in response to peroxisome proliferator-activated receptor-α activation which plays an important role in regulating carbohydrate and lipid metabolism. This study investigated the association between fibroblast growth factor 21 and prediabetes in obese patients with non-alcoholic fatty liver disease in adult population. Methods: A total of 85 obese non-alcoholic fatty liver disease patients without (n = 49) and with prediabetes (n = 36) were included. Serum fibroblast growth factor 21 levels were determined by enzyme-linked immunosorbent assay. Results: Higher fibroblast growth factor 21 serum levels were observed in patients with prediabetes, metabolic syndrome, dyslipidemia, and insulin resistance. There were significant correlations between fibroblast growth factor 21 and waist-to-stature ratio, visceral adiposity index, triglycerides, very low-density lipoproteins, alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), Quantitative Insulin Sensitivity Check Index, and Stumvoll index of insulin sensitivity. Fibroblast growth factor 21 level ≥320 pg/mL was associated with a 4.2-fold higher risk of prediabetes and ≥270 pg/mL for metabolic syndrome approximately 4 times. Conclusion: Fibroblast growth factor 21 is associated with increased risk for prediabetes, metabolic syndrome, and insulin resistance in obese patients with non-alcoholic fatty liver disease.

___

1. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-2682. [CrossRef]

2. Kaya E, Yılmaz Y. Non-alcoholic fatty liver disease: a growing public health problem in Turkey. Turk J Gastroenterol. 2019;30(10):865- 871. [CrossRef]

3. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1) :202-209. [CrossRef]

4. Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol. 2021;15(4):345-352. [CrossRef]

5. Demirtas C, Yilmaz Y. Metabolic-associated fatty liver disease: time to integrate ground-breaking new terminology to our clinical practice? Hepatol Forum. 2020;3:79-81.

6. Lebensztejn DM, Flisiak-Jackiewicz M, Białokoz-Kalinowska I, Bobrus-Chociej A, Kowalska I. Hepatokines and non-alcoholic fatty liver disease. Acta Biochim Pol. 2016;63(3):459-467. [CrossRef]

7. Ong KL, Mcclelland RL, Allison MA, et al. Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: the multi‐ethnic study of atherosclerosis. Atherosclerosis. 2019;281:200-206. [CrossRef]

8. Akour A, Kasabri V, Boulatova N, et al. Levels of metabolic markers in drug-naïve prediabetic and type 2 diabetic patients. Acta Diabetol. 2017;54(2):163-170. [CrossRef].

9. Pohl R, Haberl EM, Rein-Fischboeck L, et al. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. Eur J Clin Invest. 2017;47(1):7-18. [CrossRef]

10. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139(2):456-463. [CrossRef]

11. Alisi A, Ceccarelli S, Panera N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One. 2013;8(6):e67160. [CrossRef]

12. Watanabe M, Risi R, Camajani E, et al. Baseline HOMA IR and circulating FGF21 levels predict NAFLD improvement in patients undergoing a low carbohydrate dietary intervention for weight loss: a prospective observational pilot study. Nutrients. 2020;12(7):2141. [CrossRef]

13. Xie Q, Zhou X, Huang P, Wei J, Wang W, Zheng S. The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis. PLoS One. 2014;9(4):e92772. [CrossRef]

14. American Diabetes Association. Standards of medical care in diabetes-2019 abridged for primary care providers. Clin Diabetes. 2019;37(1):11-34. [CrossRef]

15. Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920-922. [CrossRef]

16. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645. [CrossRef]

17. Kanauchi M. A new index of insulin sensitivity obtained from the oral glucose tolerance test applicable to advanced type 2 diabetes. Diabetes Care. 2002;25(10):1891-1892. [CrossRef]

18. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59(7):1817-1824. [CrossRef]

19. Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline‐deficient diets. Gastroenterology. 2014;147(5):1073-83.e6. [CrossRef]

20. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148(2):774-781. [CrossRef]

21. Coskun T, Bina HA, Schneider MA, et al. FGF21 corrects obesity in mice. Endocrinology. 2008;149(12):6018-6027. [CrossRef]

22. Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Investig. 2010;40(10):887-892. [CrossRef]

23. Wang YS, Ye J, Cao Y-H, et al. Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis. Postgrad Med J. 2019;95(1121):134-139. [CrossRef]

24. Chen WW, Li L, Yang GY, et al. Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116(1):65-68. [CrossRef]

25. Samms RJ, Lewis JE, Norton L, et al. FGF21 is an insulin-dependent postprandial hormone in adult humans. J Clin Endocrinol Metab. 2017;102(10):3806-3813. [CrossRef]

26. Barb D, Bril F, Kalavalapalli S, Cusi K. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. J Clin Endocrinol Metab. 2019;104(8):3327-3336. [CrossRef]

27. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333-340. [CrossRef]

28. Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a pegylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019;392(10165):2705-2717. [CrossRef]

29. Watanabe M, Singhal G, Fisher FM, et al. Liver-derived FGF21 is essential for full adaptation to ketogenic diet but does not regulate glucose homeostasis. Endocrine. 2020;67(1):95-108. [CrossRef]

30. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781- 2789. [CrossRef]

___

Turkish Journal of Gastroenterology
  • ISSN: 1300-4948
  • Yayın Aralığı: Yılda 12 Sayı
  • Başlangıç: 1996
  • Yayıncı: AVES Yayıncılık

50.3b2.4b

Sayıdaki Diğer Makaleler

Helicobacter pylori Infection and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Keyvan HEYDARİ, Mohammad YOUSEFİ, Reza ALIZADEH-NAVAEI, Parisa LOTFİ, Fateme SHEYDAEE, Maedeh RAEİ, Alireza VAHDATİNİA, Amirhossein HESSAMİ, Sajjad RAFATİ, Mahmood MOOSAZADEH, Roya GHASEMİAN, Fatemeh SALEHİ, Haleh MASSOUDİ, Fatemeh GHAFFARİ-SARAVİ, Sahar RİSMANTAB

Electrogastrography in Patients with Functional Dyspepsia, Joint Hypermobility, and Diabetic Gastroparesis

Abdullah Al KAFEE, Talar CİLACI, Yusuf KAYAR, AYDIN AKAN

The 100 Most-Cited Articles in the Field of Colorectal Diseases from 1955 to 2020: A Bibliometric Analysis

Chunmei ZHANG, Mengqi LUO, Hanlong ZHU, Jian ZHOU, Lin MIAO

Is Helicobacter pylori Infection Associated with Celiac Disease? A Meta-analysis

Min YUE, Qiang CHEN, Xinxin ZHOU, Lan Lİ, Chao LU

IBD Patients’ Perception of Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic and Satisfaction with Provided Healthcare: A Cross-Sectional Study

Davor HRABAR, Petra CACIC, Alen BISCANIN, Vedran TOMASIC, Dominik KRALJ, Doris OGRESTA, Stipe PELAJIC, Zdravko DOROSULIC, Tani BABAROVIC

Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience

Arif COŞAR, Serdar DURAK

Fibroblast Growth Factor 21 as a Marker of Prediabetes in Patients with Non-alcoholic Fatty Liver Disease

Vera KARAMFİLOVA, Yavor ASSYOV, Iveta NEDEVA, Antoaneta GATEVA, Irena IVANOVA, Nikolay CHERKEZOV, Ludmila MATEVA, Zdravko KAMENOV

Turkish Validity-Reliability Study of the Celiac Disease-Specific Pediatric Quality of Life Scale

Cemal KOÇAK, Semih SANDAL, Meltem ÇÖL, Aydan KANSU, Zarife KULOĞLU, Ceyda TUNA KIRSACLIOGLU

In Vitro and In Vivo Effects of Nonsteroidal Anti-inflammatory Drugs and Aspirin on Rabbit Esophageal Epithelium

Sezgi KIPÇAK, Doğa ÇAĞANOĞLU, Pelin ERGÜN, Serhat BOR

Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?

Bilger ÇAVUŞ, Filiz AKYÜZ, Aslı ÖRMECİ, İlker ÖZGÜR, Cansu EREL, Aysun YAKUT, Ziya İMANOV, İbrahim Volkan ŞENKAL, Alpay MEDETALİBEYOĞLU, MURAT KÖSE, Metin KESKİN, Kadir DEMİR, Fatih BEŞIŞIK, Sabahattin KAYMAKOĞLU